Evaluation of cardiometabolic factors in heart failure patients
Official title: Cardiometabolic Risk Factors and Clinical Outcomes in Heart Failure: An Observational Cohort Study
Run by Ruijin Hospital · NCT06939985 · Data updated 2026-11-12
This study looks at how different health factors related to metabolism and body fat affect heart function and outcomes in people with heart failure.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 5000 (estimated) |
| Sponsor | Ruijin Hospital Academic / other |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | January 1, 2015 |
| Main results expected | May 31, 2027 |
| Study ends | May 31, 2030 |
| Registry record updated | April 23, 2025 |
| Trial ID | NCT06939985 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with chronic heart failure across various ejection fraction phenotypes.
✕Probably not a fit
Patients with an estimated survival of less than one year or those unable to provide informed consent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational cohort study investigates the impact of systemic and local cardiometabolic risk factors on cardiac remodeling and clinical outcomes in heart failure patients. It combines retrospective clinical data from the past decade with a 5-year prospective follow-up, examining various heart failure phenotypes including HFrEF, HFmrEF, HFpEF, and HFimpEF. The study analyzes metabolic factors such as blood lipid profiles and insulin resistance, alongside localized factors like epicardial and perivascular adipose tissue, to understand their associations with cardiac function and adverse cardiovascular events.
Why it matters
Potential benefit: If successful, this study could enhance risk stratification and management strategies for heart failure patients.
How similar studies have gone: Other studies have shown success in evaluating cardiometabolic factors in heart failure, but this study's comprehensive approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥ 18 years 2. Chronic HF (NYHA II\~IV), including: * HFrEF (HF with reduced ejection fraction): ① HF symptoms±signs ; ② LVEF≤40%. * HFimpEF (HF with improved ejection fraction): ① HF symptoms±signs; ② previous LVEF ≤ 40% and a follow-up measurement of LVEF \>40%. * HFmrEF (HF with mildly reduced ejection fraction): ① HF symptoms±signs; ② LVEF 41%\~49%. * HFpEF (HF with preserved ejection fraction): ① HF symptoms±signs; ② LVEF ≥50%; ③ objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of LV diastolic dysfunction/raised LV filling pressures, including raised natriuretic peptide. Exclusion Criteria: 1. Estimated survival ≤ 1 year. 2. Pregnant or lactation, or have the intention to give birth within one year. 3. Poor compliance, unable to follow-up. 4. Mental or physical status not allowing written informed consent. 5. Unwillingness to give informed consent.
Where it's running
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China Recruiting
Study contacts
- Principal investigator: Ruiyan Zhang, M.D., Ph.D. — Ruijin Hospital
- Study coordinator: Chendie Yang, M.D., Ph.D.
- Email: yangcd1029@163.com
- Phone: 0086-21-64370045-671503
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using Apple Watch data to predict heart failure outcomes
This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.
-
Comparing Aortix Device to Diuretics for Acute Heart Failure
This study is testing whether the Aortix device can help people with acute heart failure who aren't responding to diuretics feel better compared to standard treatment.
-
Myocardial Energetics Across Cardiovascular Disease Spectrum Using 31P-MRS
Researchers are testing whether phosphorus-31 magnetic resonance spectroscopy (31P-MRS) can map heart energy metabolism across healthy people and patients with various heart conditions.
-
Tailored digital support to cut sedentary time in long-term cardiac rehab
In adults in a long-term cardiac rehabilitation program, this study tests whether a personalized behavioural program with digital tools can reduce daily sitting time.
-
Registering medical data and care outcomes for ALS, SMA, and other motor disorders
This registry slowly collects routine-care information from adults with ALS, SMA, or other motor disorders to see how they’re treated and how care affects outcomes.
-
NT-proBNP–guided heart failure screening for people 65+ in rural China
This study tests whether using NT-proBNP blood tests to guide heart failure screening in adults 65 and older in rural China can find unrecognized heart problems more effectively than symptom-based screening.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.